Respiratory diseases

Exceptional knowledge, every step of the way

Our respiratory experience in both clinical practice and pharmaceutical research and development enables us to deliver exceptional personalized experiences and resolve your unique challenges across multiple respiratory indications.

The global respiratory drug market continues to grow as respiratory conditions such as asthma, idiopathic pulmonary fibrosis (IPF) and respiratory tract infections (RTI) continue to affect the global population. Particularly challenging, COPD is the third greatest cause of death globally, creating a huge need for innovation in this area.

Respiratory drug trials face unique challenges which can prove time consuming and expensive, partly because lung disease is complex and difficult to measure. Finding the right clinical trial subjects and managing large amounts of trial data also present challenges.

Our team has delivered and supported trials across innovative and generic products including drugs, medical devices and in vitro diagnostics for respiratory diseases.

Our services cover your entire product lifecycle including clinical development plan, pre-IND/IND, phase I-III and post-marketing Phase IV studies, as well as NDA submission and pharmacovigilance. We coordinate all aspects of your program through innovative monitoring and visual analytics to deliver the highest quality data you need to advance your respiratory therapy.

Your project will be designed and led by a team who understands the respiratory clinical settings and patient archetypes, connecting you with hospitals and outpatient settings to help you accelerate trial start-up and get the results you need.